Buys | $0 | 0 | 0 |
Sells | $3,185,855 | 5 | 100 |
PATOU GARY | director | 0 | $0 | 1 | $200,947 | $-200,947 |
AULIN SHERRY | Chief Financial Officer | 0 | $0 | 1 | $770,912 | $-770,912 |
MORTIMER IAN | PRESIDENT & CEO | 0 | $0 | 3 | $2.21M | $-2.21M |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise …
Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $0 and sold $3.19M worth of Xenon Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $235,534 and sold $4.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,400 shares for transaction amount of $40,334 was made by KENNEY CHRISTOPHER JOHN (Chief Medical Officer) on 2022‑01‑21.
2025-01-27 | Sale | MORTIMER IAN | PRESIDENT & CEO | 16,315 0.0216% | $40.50 | $660,806 | -3.58% | |
2025-01-24 | Sale | MORTIMER IAN | PRESIDENT & CEO | 22,468 0.0298% | $40.20 | $903,214 | -3.13% | |
2025-01-23 | Sale | MORTIMER IAN | PRESIDENT & CEO | 16,217 0.0213% | $40.08 | $649,977 | -3.11% | |
2024-12-18 | Sale | AULIN SHERRY | Chief Financial Officer | 18,709 0.0256% | $41.21 | $770,912 | -1.03% | |
2024-11-22 | Sale | PATOU GARY | director | 4,891 0.0064% | $41.09 | $200,947 | -4.13% | |
2024-03-08 | Sale | GAROFALO ELIZABETH A. | director | 2,092 0.0027% | $45.69 | $95,583 | -13.08% | |
2024-03-07 | Sale | ROBIN SHERRINGTON | EVP, Strategy & Innovation | 7,137 0.0095% | $46.28 | $330,290 | -12.81% | |
2024-03-07 | Sale | GANNON STEVEN | director | 13,000 0.0173% | $46.28 | $601,615 | -12.81% | |
2023-12-14 | Sale | PATOU GARY | director | 7,598 0.0103% | $41.05 | $311,898 | +1.21% | |
2023-12-13 | Sale | PATOU GARY | director | 18,978 0.0257% | $39.99 | $758,983 | +4.60% | |
2023-08-24 | Sale | Svoronos Dawn | director | 25,000 0.0391% | $38.70 | $967,500 | +4.70% | |
2023-06-01 | Sale | PIMSTONE SIMON N. | director | 31,713 0.0485% | $38.82 | $1.23M | +2.56% | |
2023-05-31 | Sale | PIMSTONE SIMON N. | director | 62,526 0.0956% | $38.70 | $2.42M | +2.70% | |
2023-05-30 | Sale | PIMSTONE SIMON N. | director | 37,006 0.0576% | $39.28 | $1.45M | +3.13% | |
2023-05-24 | Sale | MORTIMER IAN | PRESIDENT & CEO | 31,655 0.0482% | $41.41 | $1.31M | -4.09% | |
2023-03-24 | Sale | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 700 0.0011% | $35.01 | $24,507 | +10.88% | |
2023-03-07 | Sale | PIMSTONE SIMON N. | director | 19,232 0.03% | $36.98 | $711,199 | +6.76% | |
2022-11-25 | Sale | PATOU GARY | director | 1,937 0.0032% | $34.79 | $67,390 | +8.14% | |
2022-09-02 | Sale | AULIN SHERRY | Chief Financial Officer | 15,355 0.0238% | $39.57 | $607,597 | -3.33% | |
2022-08-31 | Sale | ROBIN SHERRINGTON | EVP, Strategy & Innovation | 8,776 0.0134% | $38.80 | $340,509 | -2.86% |
MORTIMER IAN | PRESIDENT & CEO | 31302 0.0409% | $1.11M | 2 | 4 | +28.18% |
PATOU GARY | director | 23573 0.0308% | $839,198.80 | 2 | 4 | +22.11% |
BVF PARTNERS L P/IL | 10 percent owner | 1674468 2.1876% | $59.61M | 10 | 0 | <0.0001% |
Hayden Michael R | director | 161187 0.2106% | $5.74M | 1 | 0 | +44.6% |
AZAB MOHAMMAD | director | 57561 0.0752% | $2.05M | 5 | 1 | +72.32% |
$193,151,375 | 134 | 8.18% | $2.8B | |
$11,588,217 | 69 | 42.07% | $2.65B | |
$1,376,668 | 53 | 18.46% | $2.38B | |
$1,275,975,557 | 32 | 19.44% | $2.87B | |
Xenon Pharmaceuticals Inc. (XENE) | $5,066,938 | 27 | 26.38% | $2.72B |
Increased Positions | 97 | +42.73% | 6M | +8.44% |
Decreased Positions | 90 | -39.65% | 4M | -5.74% |
New Positions | 30 | New | 2M | New |
Sold Out Positions | 21 | Sold Out | 623,017 | Sold Out |
Total Postitions | 234 | +3.08% | 77M | +2.7% |
Fmr Llc | $265,793.00 | 9.77% | 7.53M | +607,606 | +8.78% | 2024-12-31 |
Avoro Capital Advisors Llc | $200,147.00 | 7.36% | 5.67M | 0 | 0% | 2024-12-31 |
Driehaus Capital Management Llc | $159,667.00 | 5.87% | 4.52M | -75,126 | -1.64% | 2024-12-31 |
Wellington Management Group Llp | $133,425.00 | 4.91% | 3.78M | -65,836 | -1.71% | 2024-12-31 |
Braidwell Lp | $102,921.00 | 3.78% | 2.91M | +206,709 | +7.63% | 2024-12-31 |
Janus Henderson Group Plc | $101,254.00 | 3.72% | 2.87M | +314,363 | +12.32% | 2024-12-31 |
Commodore Capital Lp | $96,777.00 | 3.56% | 2.74M | +40,000 | +1.48% | 2024-12-31 |
Polar Capital Holdings Plc | $95,281.00 | 3.5% | 2.7M | +253,012 | +10.35% | 2024-12-31 |
Capital International Investors | $89,967.00 | 3.31% | 2.55M | -33,962 | -1.32% | 2024-12-31 |
Capital World Investors | $81,043.00 | 2.98% | 2.29M | -387,000 | -14.43% | 2024-12-31 |